Examples include the humanized anti-VEGF monoclonal antibody bevacizumab, approved in the clinic for a number of malignancies [4], and the VEGF-Trap protein aflibercept formed by the fusion of the immunoglobulin domain of VEGFR with the human IgG Fc fragment, approved for second-line treatment of metastatic colorectal cancer (CRC) [5]; both compounds are in general used in combination with chemotherapy. Here, VEGFA is linked to colorectal carcinoma.